MTMichael M. Tunney

Michael M. Tunney

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael M. Tunney has a total of 561 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microfluidic Production and Characterisation of Cyclosporine A-Loaded Lipid–Chitosan Hybrid Nanoparticles as Candidate Pulmonary Drug Delivery Systems

    by Pierpaolo Palermo, Davide De Angelis, Elisa Sgarbi, Irene Bassanetti, Michael M. Tunney, Dimitrios A. Lamprou

    Backgorund/Objectives: Respiratory diseases represent a substantial global health burden and require effective localised pulmonary delivery strategies, particularly for poorly water-soluble therapeutic molecules. Nanoparticle-based drug delivery systems, especially those manufactured using microfluidics, have emerged as promising approaches to overcome pulmonary barriers, enhance local drug retention, and reduce systemic side effects. Among these nanocarriers, solid lipid nanoparticles (SLNs) and solid hybrid nanoparticles (SHNs) combine biocompatibility with controlled release and improved formulation stability. Methods: In this study, SLNs and lipid–chitosan SHNs were developed using microfluidic technology as candidate platforms for pulmonary drug delivery, with Cyclosporine A (CyA) used as a model hydrophobic cyclic peptide. Nanocarriers were produced using 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol as lipids, with low-molecular-weight chitosan incorporated to obtain hybrid systems. Physicochemical properties were evaluated using dynamic light scattering (DLS) and ζ potential measurements, while morphology and structural organisation were investigated using transmission electron microscopy (TEM), Fourier-transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC). Results: The microfluidic approach enabled the production of nanoparticles with controlled sizes below 200 nm, narrow size distributions, and good reproducibility. In addition, the SHNs exhibited a positive surface charge, high encapsulation efficiency (~80%), and good colloidal and thermal stability. In vitro release studies showed an initial burst release followed by sustained CyA release, reaching approximately 94% cumulative release within 6 h. The Korsmeyer–Peppas model was used as the standard kinetic model. No blank nanoparticles were used as controls in the EE and release assay. Conclusions: Overall, these findings support further investigation of microfluidic-produced lipid and hybrid nanoparticles as candidate platforms for pulmonary drug delivery.

  • Open Access

    Molecular endotyping in people with bronchiectasis based on response to antibiotic treatment: iBEST study

    by Gisli G. Einarsson, Laura J. Sherrard, Andrew J. Lee, Jack Carson, Andrew Marshall, Aya Alkhatib, Vanessa Brown, Deirdre F. Gilpin, Gerhild Angyalosi, Michael R. Loebinger, et al.

    Background: Culture-independent molecular techniques could potentially be used to measure microbiological efficacy in response to antibiotic treatment and improve understanding of the role of the airway microbiota in determining response in patients with chronic respiratory disease. Methods: Using molecular methods, we analysed changes in the sputum microbiota in samples from 107 participants with bronchiectasis recruited to the iBEST-1 study, and defined community endotypes based on response to tobramycin inhalation powder (TIP) treatment. The relationship between microbiota metrics in these endotypes and clinical and inflammatory biomarkers were also determined. Results: There was a significant reduction in Pseudomonas aeruginosa density, measured by quantitative polymerase chain reaction (qPCR), between Days 1 and 29 for participants in the TIP treatment (n=63; p0.05) group. Based on decrease in P. aeruginosa density ( oprL copies·mL −1 ) over 28 days, two clusters of participants receiving TIP were observed and stratified as either responders (≥2Log 10 ; n=26) or non-responders (10 ; n=37). In responders, a shift to a microbial community structure less dominated (p=0.018) by a pathogen was apparent and associated with a greater improvement in inflammatory and fewer participant exacerbations in the following 6 months (27% versus 49%; p=0.117) when compared to non-responders. Lung function was higher at Day 1 in responders ( median =64.6% predicted) than non-responders (μ̃ median =50.3% predicted) and independently predicted response to treatment with TIP (p=0.013). Conclusions: qPCR may be a useful, culture-independent microbiological efficacy end-point in clinical trials. Using qPCR, participants with bronchiectasis were stratified into endotpyes which predicted response to antimicrobial treatment, potentially allowing for a more personalised approach to therapy.


  • Open Access

    Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): Results of a multi-centre randomised controlled trial

    by Barry J Plant, Gisli G Einarsson, Kevin F Deasy, Darren Dahly, Pradeep K. Singh, Peter J. Barry, Christopher H. Goss, Isabelle Fajac, Tamara Vagg, Isabelle Durieu, et al.

    Background: This study explores the effectiveness and safety of microbiome-directed-antimicrobial-therapyversususual-antimicrobial-therapy in adult cystic fibrosis pulmonary exacerbations.Methods: A multi-centre two-arm parallel randomised control trial conducted across Europe/North-America enrolled 223 participants (January 2015 - August 2017). All participants were chronically colonised withPseudomonas aeruginosaand were randomised 1:1 into two study-arms. The “usual-therapy group” received 2-weeks of IV ceftazidime 3g thrice-daily (for allergies: aztreonam 2g thrice-daily) and tobramycin 5–10mg·kg−1once-daily. The “microbiome-directed group” received the same usual-therapy plus an additional antibiotic with greatest presumed activity against the 2nd, 3rd and 4th most abundant genera present in the sputum microbiome, selected by a Consensus Expert Treatment Panel. The primary outcome was change in percentage of predicted FEV1(ppFEV1) at 14 days post initiation of antibiotics. Secondary outcomes examined ppFEV1at 7 days, 28 days, and 3 months; time-to-next exacerbation; symptom burden at 7 days; Health Related Quality of Life (HRQoL) at 28 days; and number of exacerbations and IV antibiotic days at 12 months.Results: 149 participants had an eligible exacerbation (usual-therapy n=83, microbiome-directed therapy n=66). There was no difference between the groups for ppFEV1at day 14 (−1.1%, 95%CI −3.9 to 1.7; p=0.46), or ppFEV1measured at other time-points, or for time-to-next exacerbation (microbiome-directedversususual-therapy Hazard Ratio 0.91 [95%CI 0.60 to 1.38; p=0.66]). The microbiome-directed group trended to have more IV days (median 42versus28; p=0.08) and more subsequent exacerbations (median 3versus2; p=0.044) the following year. There were no appreciable differences in symptom burden; however, HRQoL sub-scores were consistently worse in the microbiome-directed group (−4.3 pointsversususual therapy (95%CI −8.3 to −0.3, p=0.033).Conclusion: The addition of a third antibiotic based on sputum microbiome sequencing analysis did not result in improved clinical outcomes.


  • Open Access

    Airway total bacterial density, microbiota community composition and relationship with clinical parameters in bronchiectasis

    by Zina Alfahl, Gisli G. Einarsson, J. Stuart Elborn, Deirdre F. Gilpin, Katherine O'Neill, Kathryn Ferguson, Adam T. Hill, Michael R. Loebinger, Mary Carroll, Timothy Gatheral, et al.


  • Effect of treatment with tobramycin on the airway microbiota and resistome in bronchiectasis patients chronically colonised with Pseudomonas aeruginosa: iBEST study

    by Michael M Tunney, Gisli G Einarsson, Andrew J Lee, Aya Alkhatib, Jack Carson, Andrew Marshall, Stephen Carson, Deirdre F Gilpin, Gerhild Angyalosi, Vincent Malaterre, et al.

    Introduction: This study determined changes in the antimicrobial resistome and airway microbiota following treatment with tobramycin inhalation powder (TIP) or placebo in the iBEST study. Methods: DNA was extracted from sputum collected at baseline and at day 29 (Day 1 vs Day 29) following treatment with TIP (224mg daily; n=11 patients) or placebo (n=5 patients). Shotgun-metagenomic sequencing (sgNGS) was performed on the Illumina Novaseq platform. P. aeruginosa density was determined by both total viable count (TVC) and qPCR of the oprL gene with total bacterial density measured by qPCR of the 16S rRNA gene. Resistome profiles were determined by mapping reads to the Comprehensive Antibiotic Resistance gene Database (CARD). Results: Using sgNGS sequences, reads mapped to 62 different resistance genes. Differences in resistance gene prevalence for multiple targets were observed pre- and post-treatment and were primarily associated with samples from patients receiving TIP. Limited or no difference was observed for those receiving placebo. Differences in resistome profiles were strongly aligned with a decrease in P. aeruginosa density determined by TVC (Day 1 vs. Day 29; TIP: pP. aeruginosa density within the community. Supported by EU/EFPIA IMI iABC grant no° 115721

  • qPCR and 16S rRNA marker-gene sequencing as endpoints for clinical trials of antimicrobials: iBEST study

    by Michael M Tunney, Gisli G Einarsson, Andrew J Lee, Aya Alkhatib, Jack Carson, Andrew Marshall, Stephen Carson, Deirdre F Gilpin, Gerhild Angyalosi, Vincent Malaterre, et al.

    Introduction: qPCR can be useful for the detection and absolute quantification of target genes, whilst 16S rRNA MiSeq sequencing (NGS) provides data on the relative abundance of taxa within a community. Here we compare total, P. aeruginosa (PA) and H. influenzae (HI) bacterial density with ecological metrics obtained by NGS. Methods: Sputum samples (n=219) collected in the iBEST study at Days 1, 8 and Day 29 from patients receiving tobramycin inhalation powder (TIP; n=54) and placebo (n=19) were analysed by qPCR and NGS. The relationship between ecological metrics and total bacterial (16S rRNA), PA (oprL and ecfX) and HI (hpD and smpB) density was compared. Results: There was a significant reduction in total bacterial density between Day 1 and 29 in the TIP group (p< 0.001), with no difference in the placebo group (p=0.980). A significant decrease in PA density with TIP treatment was also apparent for both qPCR targets (oprL: p<0.001; ecfX: p<0.001), with no difference for the placebo group (p=0.740 and p=0.970, respectively). There was a significant negative correlation between Shannon-Wiener diversity and oprL and ecfX gene copy number (r=-0.427; p<0.001 and r=0.406; p<0.001), with a positive association between dominance and PA copy number (r=0.440; p<0.001 and r=0.430; p0.05) for HI. Conclusion: Higher density of pathogens, such as PA, was associated with lower community diversity and higher dominance, highlighting that qPCR may be a useful end-point in clinical studies. Supported by EU/EFPIA IMI iABC grant n° 115721

  • Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist

    by Michael M. Tunney, Peter Wark

    Tweetable abstract Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis results in improved clinical outcomes, but infection and inflammation persisthttps://bit.ly/3PRaRwZ


  • A mechanistic analysis of the effect of valaciclovir for EBV suppression on airway inflammation and microbiome in COPD

    by D Linden, H Guo-Parke, G Einarsson, S Carson, A Lee, D Fairley, D Singh, M Tunney, D Mcauley, C Taggart, et al.

    Introduction: Airway immunohistochemistry in COPD indicates that Epstein-Barr virus (EBV) detection is associated with CD8+ accumulation and depletion of host defence proteins including secretory IgA. The effects of EBV suppression on airway inflammation and microbiome have not been studied previously. Methods: Sputum biomarkers and microbiota were pre-specified exploratory outcomes from EViSCO (NCT03699904) a randomised, double-blind, placebo-controlled trial of valaciclovir (1 gram TID for 8 weeks) for EBV suppression in COPD. Sputum cell counts, cytokines, microbiome, bacterial 16S and H. influenzae load were characterised at baseline and week 8 using ELISA, 16S rRNA and qPCR. Results: Valaciclovir was associated with a between-group reduction in sputum total leukocyte count (difference 2.89;[95% CI 1.5 x106-7.4 x 106];p=0.003) and a 6-fold within-group reduction in IP-10 (p=0.008). An exploratory cohort underwent microbiome characterisation demonstrating that Firmicutes, Proteobacteria and Bacteroidetes were the dominant taxa in both groups. There was no between-group difference in α-diversity or bacterial load (p=0.61) at week 8. However, valaciclovir was associated with a -0.7 (±1.8) log reduction in H. influenzae load (p=0.03) and a within-group trend towards increased relative abundance of Bacteroidetes (p=0.07). Conclusion: EBV suppression with valaciclovir attenuated airway inflammation and H. influenza load. These findings justify further mechanistic evaluation through a trial adequately powered to evaluate sputum microbiome as a pre-specified primary outcome.

  • Open Access

    The Effects of Agrimonia pilosa Ledeb, Anemone chinensis Bunge, and Smilax glabra Roxb on Broiler Performance, Nutrient Digestibility, and Gastrointestinal Tract Microorganisms

    by Rebekah L. McMurray, M. Elizabeth E. Ball, Mark Linton, Laurette Pinkerton, Carmel Kelly, Jonathan Lester, Caroline Donaldson, Igori Balta, Michael M. Tunney, Nicolae Corcionivoschi, et al.

    Poultry farming is growing globally, particularly in developing countries, to meet the demands of growing populations for poultry meat and eggs. This is likely to lead to an increase in the use of antibiotics in poultry feed, thus contributing to the development and spread of antibiotic resistance which, poses a serious threat to human and animal health worldwide. One way of reducing this threat is to reduce the use of antibiotics in poultry production by finding effective and sustainable antibiotic alternatives that can be used to support poultry health and productivity. Therefore, this study evaluates the incorporation of three medicinal plants, Anemone chinensis Bunge, Smilax glabra Roxb, and Agrimonia pilosa Ledeb, in poultry feed on production performance, nutrient digestibility, and bacteria in the chicken caecum in a 35-day performance trial with 420-day-old male Ross 308 broilers. Groups of randomly selected chicks received one of six dietary treatments. These included five experimental diets of reduced nutrient specifications as a negative control (NC); with amoxicillin as a positive antibiotic control (PC1); with A. pilosa Ledeb (NC1); with A. chinensis Bunge (NC2); and with S. glabra Roxb (NC3). One other positive control diet contained the recommended nutrient specification (PC2). Weight gain and feed intake were measured weekly and used to calculate the feed conversion ratio as performance parameters. Bacteria were enumerated from chicken caecum using a traditional plating method and selective agar. S. glabra Roxb and A. chinensis Bunge showed comparable effects to amoxicillin with significantly increased weight gain in birds offered these diets, compared to those offered the negative control from days 0 to 35 (p < 0.001). S. glabra Roxb exhibited effects similar to the amoxicillin control group with an improved feed conversion ratio (p < 0.001). In addition, S. glabra Roxb decreased numbers of E. coli and Campylobacter spp. on days 21 (p < 0.05) and 35 (p < 0.01) and increased numbers of lactic acid bacteria comparable to the antibiotic group on days 14 (p < 0.001) and 35 (p < 0.01). The findings of this in vivo trial highlight the potential of S. glabra Roxb and A. chinensis Bunge as beneficial feed material to promote poultry health and productivity in the absence of antibiotics.